ArticleBreast cancer research and treatment2025
Disparities in delays and outcomes in patients with HER2-positive breast cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeNeoadjuvant chemotherapy (NACT) is often the preferred systemic treatment modality for advanced breast tumors. Delays in NACT initiation are associated with worse outcomes although it is unclear which patients are at the highest risk for delays and whether these delays impact pathologic complete response (pCR). We sought to determine the incidence, predictors, and cancer-related outcomes associated with delays in NACT initiation among patients with HER2-positive (HER2 +) breast cancer in the modern era.
methodsWe retrospectively analyzed a cohort of patients with stage II-III HER2 + breast cancer who were treated with NACT and surgery using the National Cancer Database. Multivariable logistic regression, adjusted for demographic, socioeconomic and tumor characteristics, was used to identify characteristics associated with and the likelihood of achieving a pCR with delays in NACT initiation.
results56,868 patients were included in the analysis. Delays in NACT initiation of > 60 days from diagnosis was observed in 9% of patients. In a multivariable analysis, patients who were Black (OR 1.88 95%CI 1.74-2.04), Hispanic (OR 2.19, 95%CI 2.00-2.39), had Medicaid (2.14, 95%CI 1.97-2.32), or no insurance (2.39, 95%CI 2.09-2.72) were more likely to be delayed. Delay was associated with a lower likelihood of achieving pCR (OR 0.86 95% CI 0.81-0.92) and an increased risk of death (HR 1.15 95%CI 1.03-1.29).
conclusionThere are racial, ethnic, and socioeconomic disparities in NACT initiation delays and an association with worse cancer-related outcomes. Future studies and interventions are needed to mitigate these delays.
Indexed as
Identifiers
41385136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.